Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Royalty PharmaPlc stake
total: 670
Viking Global Investors RPRX trades
- Total transactions:
- 22
- New positions:
- 1
- Sold out:
- 1
- Added:
- 12
- Reduced:
- 8
- Held since:
- 2020 Q2
- Held for:
- 21 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Royalty PharmaPlc (RPRX) shares. To date, the estimated cost basis is nearly $39.37 for "buy" trades and estimated average "sell" price is $35.78. Viking Global Investors first purchased RPRX in 2020 Q2, initially acquiring about 2.51M shares. Since the initial investment in Royalty PharmaPlc (RPRX), Viking Global Investors has made 21 more transactions.
When did Ole Andreas Halvorsen sell Royalty PharmaPlc (RPRX)?
Ole Andreas Halvorsen sold off the entire Royalty PharmaPlc (RPRX) position in 2025 Q3.
When did Ole Andreas Halvorsen buy Royalty PharmaPlc (RPRX)?
Ole Andreas Halvorsen first invested in Royalty PharmaPlc (RPRX) in 2020 Q2 at the reported quarter-end price of $48.55 per share.
What's the cost basis of Viking Global Investors's RPRX stake?
The estimated cost basis for Royalty PharmaPlc (RPRX) stake is around $39.37 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $39.36
- Weighted AVG sell price:
- $35.78
Ole Andreas Halvorsen's historical trades in Royalty PharmaPlc
22 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$36.03
|
|
-100% (-2,597,460)
|
-0.27%
|
|
2025 Q2
|
0.27%
|
2,597,460
|
$36.03
|
$93,586,484
|
-75.41% (-7,966,479)
|
-0.91%
|
|
2025 Q1
|
1.04%
|
10,563,939
|
$31.13
|
$328,855,421
|
-13.47% (-1,643,946)
|
-0.17%
|
|
2024 Q4
|
1.01%
|
12,207,885
|
$25.51
|
$311,423,146
|
+0.94% (+113,864)
|
+0.01%
|
|
2024 Q3
|
1.25%
|
12,094,021
|
$28.29
|
$342,139,854
|
+1.04% (+123,963)
|
+0.01%
|
|
2024 Q2
|
1.21%
|
11,970,058
|
$26.37
|
$315,650,429
|
+4.22% (+484,511)
|
+0.05%
|
|
2024 Q1
|
1.30%
|
11,485,547
|
$30.37
|
$348,816,062
|
+13.86% (+1,398,130)
|
+0.16%
|
|
2023 Q4
|
1.04%
|
10,087,417
|
$28.09
|
$283,355,544
|
+6.58% (+623,216)
|
+0.06%
|
|
2023 Q3
|
1.04%
|
9,464,201
|
$27.14
|
$256,858,415
|
-3.93% (-386,731)
|
-0.04%
|
|
2023 Q2
|
1.24%
|
9,850,932
|
$30.74
|
$302,817,650
|
-12.08% (-1,353,317)
|
-0.2%
|
|
2023 Q1
|
1.89%
|
$36.03
|
+11.95% (+1,195,738)
|
|||
|
2022 Q4
|
1.98%
|
$39.52
|
-8.02% (-873,083)
|
|||
|
2022 Q3
|
2.02%
|
$40.18
|
-12.04% (-1,489,100)
|
|||
|
2022 Q2
|
2.38%
|
$42.04
|
+14.92% (+1,606,222)
|
|||
|
2022 Q1
|
1.70%
|
$38.96
|
+4.35% (+449,094)
|
|||
|
2021 Q4
|
1.18%
|
$39.85
|
+149.13% (+6,174,870)
|
|||
|
2021 Q3
|
0.41%
|
$36.14
|
+27.85% (+901,854)
|
|||
|
2021 Q2
|
0.40%
|
$40.99
|
+57.08% (+1,176,901)
|
|||
|
2021 Q1
|
0.27%
|
$43.62
|
-9.85% (-225,247)
|
|||
|
2020 Q4
|
0.31%
|
$50.05
|
+17.40% (+338,936)
|
|||
|
2020 Q3
|
0.30%
|
$42.07
|
-22.54% (-566,921)
|
|||
|
2020 Q2
|
0.53%
|
$48.55
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.